The state-of-the-art Pirche platform combines genetic typing with real-time AI-supported immunological simulations of protein-protein interactions, providing precise, personalized medical decision support in the fields of transplant medicine and immunotherapy to Nephrology, Oncology and Leukemia specialists. The fully digital technology relies on standard wet test results performed in clinical labs that are already standard of care. Pirche is connected through APIs with the IT systems of the leading laboratory service providers and is ‘PLUG AND PLAY’.
Our AI-supported technological platform allows physicians and specialists in the above three fields to make informed decisions on the transplant interventions necessary or — for the patients suffering from cancer — their best suited treatment plans, based on their genetic make-up. The medical evidence of the technology is proven with 55+ peer reviewed publications on 200,000+ patient cases. With Pirche, patients have improved outcomes, fewer complications and a better quality of life; payers can expect less expenses per patient and hospitals can improve their transplantation outcomes and cancer treatment success rates.
Pirche’s proprietary technology is protected in the USA, EU and other countries by 25 issued patents with additional patents pending. Pirche additionally owns the exclusive commercial rights for Linked Recognition, the sequential interaction of B-Cell and T-Cell Epitope Matching, globally and for all applications.
It is our strategy to provide the Pirche web platform through SaaS agreements and by partnering with the industry. More than 850 leading clinics worldwide are already registered users of the platform and Pirche has running contracts with the top tier service providers of HLA typing and antibody analysis diagnostics worldwide. Furthermore, Pirche has become a corner partner of government backed research in the EU, Germany and Canada.
Pirche AG is a German privately held joint-stock company (Aktiengesellschaft) founded in Berlin by Thomas Klein whose management possesses a track record over the past 25 years in biotechnology, bioinformatics and IT. The basic scientific work for this groundbreaking technology was done at the University Medical Center Utrecht (UMCU) in The Netherlands by Dr. Eric Spierings and his team.
To learn more contact us via e-mail, LinkedIn or get in touch directly using our website’s live chat function.
P.S. In case you’ve been wondering what Pirche stands for, here’s the answer: Predicted Indirectly ReCognizable HLA Epitopes.
The Pirche platform supports physicians and clinical laboratories in making better decisions regarding organ allocation based on existing lab data and analyses. Globally, more than 600,000 patients await a kidney transplant each year, however only about 110,000 of these patients will even have a chance at receiving such a transplant. Decisions based on Pirche’s precise algorithms improve the survival rate of transplanted organs in cases of both deceased and living donation, including paired donations. In the medium term, this reduces the number of patients waiting for a second or third transplant. At the same time, Pirche increases the number of organs transplanted by the increased specificity of histocompatibility matching, leading to more lives being saved. Pirche can be used in the transplantation of all organ types and its medical evidence has been demonstrated in over 40 scientific publications considering over 75,000 patient cases.
With its technological platform, Pirche has access to the $20 billion worldwide organ transplantation market and over 650 leading hospitals worldwide have already begun using our services. Through IT interfaces, the Pirche platform can also be accessed through the software suites of the leading providers of laboratory services such as Thermo Fisher, Immucor and others. By partnering with the industry, it is our strategy to leverage Pirche’s unique prediction capabilities to enable the precise, lifelong monitoring of patients to such a high degree that immunosuppressant dosing levels can be individually controlled. For cell-free DNA (cfDNA) transplant monitoring tools, PIRCHE offers the decisive entry point for personalized patient monitoring and immunosuppressant dosing.
Click the link below for an explanation of the molecular function of our technology in solid organ transplantation.
In patients whose immune systems or bone marrow are incapable of functioning properly due to malignant and non-malignant diseases including leukaemia, lymphoma and multiple myeloma, hematopoietic Stem Cell Transplantation (SCT) is a life-saving treatment option. Through SCT, hematopoietic stem cells are infused into the immunocompromised patients to stimulate healthy blood cell production.
The Pirche technology platform enables doctors and medical laboratory staff to better identify and select donors and recipients for cord blood (CB), haploidentical (Haplo) and mismatched unrelated donor (MMUD) transplantation cases, greatly improving the outcome of these patients. Our markets are all hematopoietic stem-cell transplantations (over 50,000 per year), platelet transfusions (85,000,000 units per year) and induced pluripotent stem-cell transplantations (iSPC). With the SCT market valued at over $2 billion and the market for iPSC projected to reach $3.8 billion by 2024, Pirche is already strongly positioned to access these markets thanks to the extensive network of clinical laboratories and hospitals using our platform and our collaborations with our industry partners.
Have a look at the following link for a better understanding of how the Pirche algorithm is used in the SCT domain.
PIRCHE Algorithm in Hematopoietic Stem Cell Transplantation (SCT)
Every year 17 million people will be diagnosed with cancer. Furthermore, 9.5 million deaths are attributed to cancer annually. Through the European Commission funded ULISES Project, PIRCHE is part of a consortium developing technology to train the immune system to detect and fight cancer cells. With pancreatic cancer as the basis for this research, the PIRCHE technology is being used to execute an immunological strategy that “reprograms” cancer cells and enables the immune system to identify and destroy them. In the oncological context, our algorithm is being adapted to assist in programming cancer cells with the maximum number of epitope mismatches between their HLA and those of the rest of the patient’s body. This process identifies which epitopes the body is most capable of recognizing and fighting and offers new hope to patients suffering from hard to treat cancers.
The market for cancer therapeutics is predicted to reach $180.19 billion by 2026. Pirche is positioned to play a central role in individualizing cancer treatments upon successful completion of the ULISES Project in 2023.
Click through below for an easy-to-follow visual demonstration of how the PIRCHE algorithm functions in the oncological space.
This website uses cookies for functionality and to make your visit better. Learn more about our privacy policy.
